Hyloris Pharmaceuticals Future Growth
Future criteria checks 5/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Hyloris Pharmaceuticals.
Key information
118.2%
Earnings growth rate
-1.8%
EPS growth rate
| Pharmaceuticals earnings growth | 14.2% |
| Revenue growth rate | 79.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 07 Sep 2023 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 47 | 14 | N/A | -2 | 2 |
| 12/31/2024 | 22 | -1 | N/A | -11 | 2 |
| 12/31/2023 | 13 | -5 | N/A | -7 | 2 |
| 6/30/2023 | 3 | -12 | -12 | -11 | N/A |
| 3/31/2023 | 3 | -12 | -13 | -12 | N/A |
| 12/31/2022 | 3 | -11 | -14 | -13 | N/A |
| 9/30/2022 | 3 | -10 | -12 | -11 | N/A |
| 6/30/2022 | 3 | -8 | -9 | -8 | N/A |
| 3/31/2022 | 3 | -10 | -11 | -10 | N/A |
| 12/31/2021 | 3 | -12 | -12 | -11 | N/A |
| 9/30/2021 | 2 | -12 | -13 | -13 | N/A |
| 6/30/2021 | 1 | -12 | -14 | -14 | N/A |
| 3/31/2021 | 1 | -10 | -7 | -7 | N/A |
| 12/31/2020 | 0 | -7 | -5 | -5 | N/A |
| 9/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 6/30/2020 | 0 | -8 | -5 | -4 | N/A |
| 3/31/2020 | 0 | -6 | -8 | -6 | N/A |
| 12/31/2019 | 0 | -5 | -6 | -5 | N/A |
| 12/31/2018 | 0 | -6 | -5 | -5 | N/A |
| 12/31/2017 | 0 | -4 | -4 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HYL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: HYL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: HYL is expected to become profitable in the next 3 years.
Revenue vs Market: HYL's revenue (79.1% per year) is forecast to grow faster than the Belgian market (7.5% per year).
High Growth Revenue: HYL's revenue (79.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HYL's Return on Equity is forecast to be high in 3 years time